Avadel Pharmaceuticals (AVDL) Enterprise Value (2016 - 2022)
Historic Enterprise Value for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to -$106.5 million.
- Avadel Pharmaceuticals' Enterprise Value rose 4120.42% to -$106.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$106.5 million, marking a year-over-year increase of 4120.42%. This contributed to the annual value of -$157.2 million for FY2021, which is 2898.84% up from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Enterprise Value is -$106.5 million, which was up 4120.42% from -$104.1 million recorded in Q2 2022.
- Avadel Pharmaceuticals' 5-year Enterprise Value high stood at -$64.2 million for Q4 2019, and its period low was -$238.6 million during Q2 2020.
- Its 5-year average for Enterprise Value is -$144.8 million, with a median of -$125.3 million in 2018.
- Per our database at Business Quant, Avadel Pharmaceuticals' Enterprise Value skyrocketed by 5970.78% in 2019 and then plummeted by 24508.87% in 2020.
- Over the past 5 years, Avadel Pharmaceuticals' Enterprise Value (Quarter) stood at -$99.9 million in 2018, then soared by 35.79% to -$64.2 million in 2019, then crashed by 245.09% to -$221.4 million in 2020, then grew by 28.99% to -$157.2 million in 2021, then skyrocketed by 32.28% to -$106.5 million in 2022.
- Its Enterprise Value stands at -$106.5 million for Q3 2022, versus -$104.1 million for Q2 2022 and -$123.5 million for Q1 2022.